Carnosol

Carnosol: A Comprehensive Reference

1. Identity, Chemical Characterization, and Natural Sources

Chemical Identity

Carnosol (systematic IUPAC name: (4aR-(4aalpha,9alpha,10abeta))-1,3,4,9,10,10a-hexahydro-5,6-dihydroxy-1,1-dimethyl-7-(1-methylethyl)-2H-9,4a-(epoxymethano)phenanthren-12-one) is a dietary phenolic diterpene with an empirical formula C₂₀H₂₈O₄, and is a derivative of carnosic acid containing a lactone ring. The compound is registered under CAS number 5957-80-2. Carnosol is an ortho-diphenolic diterpene that contains an abietane carbon skeleton with hydroxyl groups at positions C-11 and C-12 and a lactone moiety across the B ring.

It is a naturally occurring polyphenol that is produced by the oxidative degradation of carnosic acid and is found in many herbs including rosemary (Rosmarinus officinalis) and sage (Salvia officinalis). Carnosol is also referenced in the literature by the synonym NSC 39143.

Biosynthetic Origin: The Relationship Between Carnosic Acid and Carnosol

The biosynthetic origins of carnosol are critically important to understanding its presence in plant material and commercial preparations. Carnosol is an oxidative artifact of carnosic acid. This oxidation takes place in the presence of oxygen both after the harvesting of rosemary or sage in leaves left to dry in air — it can be demonstrated that the freshly cut leaves of rosemary do not contain carnosol — and when the leaves are subjected to extraction with solvents or when the extracts themselves are subjected to conventional operations of fractionation, enrichment and purification. In other words, carnosol is not native to the intact, fresh plant; it arises during drying, processing, and storage.

Pisiferic acid represents the starting material that has been used for the semi-synthetic process of carnosic acid. Carnosic acid is then oxidized to form carnosol. Industrial processes to convert carnosic acid to carnosol have been developed using oxidizing agents such as hydrogen peroxide and peracids, with the aim of enriching extracts in this biologically active compound.

Concentration in Plant Material

Dried leaves of rosemary or sage (Salvia officinalis) contain between 1.5 and 2.5% carnosic acid and only about 0.3–0.4% carnosol. By contrast, lipophilic rosemary or sage extracts contain approximately 10–30% carnosic acid, and the proportion of carnosol in such extracts depends heavily on the degree of oxidative processing that has occurred. The most well-studied bioactive compounds in rosemary are carnosic acid, carnosol, caffeic acid, and its derivative rosmarinic acid.

Other Botanical Sources

Carnosol is a phenolic compound isolated from culinary herbs including sage, oregano, and rosemary. It has also been identified in Lepechinia hastata, a medicinal plant of Baja California, where it was reported as a diterpene antibiotic. Well before its chemical structure was fully elucidated, carnosic acid (under the name "salvin") and similar compounds of the ferruginol type were extracted from Salvia carnosa Dougl.

Common Forms and Preparations

Carnosol is encountered in commerce in several forms. It occurs naturally in dried rosemary and sage leaf used as culinary spices. It is present in standardized lipophilic rosemary or sage extracts that are approved as food antioxidants. Carnosol is one of the major polyphenols used to standardize rosemary extracts approved as a food preservative. Extracts of rosemary (designated E 392 in the European Union) have been authorized for use as food additives in several food categories with maximum levels. In dietary supplement form, carnosol may be found in standardized rosemary leaf extracts, sometimes combined with other herbs. Isolated, high-purity carnosol (≥98% purity) is also available as a research chemical, though such preparations are designated for laboratory use only.

2. Traditional and Historical Use

Rosemary in Mediterranean Cultures

Although carnosol as an isolated molecule was first described in the scientific literature in the twentieth century, the plants that are its source — primarily rosemary and sage — have extremely long documented histories of use. Carnosol is a natural compound extracted mainly from rosemary and sage, which are both common ingredients used in traditional Mediterranean cuisine. Fresh and dried leaves of rosemary are frequently used in traditional Mediterranean cuisine and in folk medicine.

The plant has been used in traditional medicine for its astringent, tonic, carminative, antispasmodic, and diaphoretic properties. Rosemary has a long tradition of use as a tonic, stimulant, and to relieve headaches, head colds, nervous tension, and indigestion. The herb is used to relax spasms, relieve pain, stimulate the liver, and improve digestion. Rosemary is a symbol of friendship, loyalty, and remembrance, and has historically been carried by mourners at funerals. Greek scholars wore garlands of rosemary ostensibly to sharpen their wits.

From a certain point in time, a brain-activity-boosting role for rosemary is attested, which is conceptualized as a "drainage of the brain that reinvigorates it, brings it back to a drier, denser, and more concentrated state, and refocuses it on its substance and activity."

Sage in Traditional Medicine

Carnosic acid is a diterpenoid abundantly present in plants belonging to the genera Rosmarinus and Salvia of the family Lamiaceae, accounting for their application in traditional medicine. In local and traditional medicine, rosemary and sage have been used for inflammation-related diseases. Sage (Salvia officinalis) was used in Greco-Roman medicine and throughout the medieval European herbal tradition for similar purposes: digestive complaints, fever, sore throat, and as a preservative for food. The European Scientific Cooperative on Phytotherapy (ESCOP) has produced monographs for both Rosmarini folium (rosemary leaf) and Salviae folium (sage leaf), which codify their traditional indications.

Key Note on Attribution

It must be emphasised that traditional-use records pertain to whole-plant preparations of rosemary and sage — teas (infusions/decoctions), tinctures, essential oils, and culinary use — and not to isolated carnosol. The association of carnosol with specific traditional therapeutic applications is an inference drawn by modern researchers, not a historical fact documented for this individual compound. While isolated carnosic acid (and by extension carnosol) lacks documented traditional use in isolation, it is a major bioactive component in rosemary extracts, which have been used in Mediterranean folk medicine. Historical applications focused on antioxidant preservation rather than specific medicinal properties of individual diterpenes.

3. Key Active Compounds and Established Mechanisms of Action

Antioxidant Mechanisms

Carnosol has been proven to have potent antioxidant effects in cell-free, in vitro cell culture, and in vivo animal models. The antioxidant activity operates through multiple complementary pathways. First, carnosol directly scavenges reactive oxygen species (ROS): it scavenges peroxyl and hydroxyl radicals and inhibits lipid peroxidation in cell-free assays. Second, it activates endogenous enzymatic antioxidant defenses.

Carnosol exhibits antioxidant properties by directly scavenging reactive oxygen species (ROS) and modulating endogenous defense mechanisms in neural cells. Its antioxidant effects, together with those of the related compound carnosic acid, contribute to neuroprotection in neurodegenerative disorders through modulation of the Nrf2/ARE molecular pathway.

Carnosol activates Nrf2 via phosphorylation of the upstream kinase Akt. Transfection of cells with dominant negative Nrf2 or treatment with a pharmacological inhibitor of Akt abrogated carnosol-induced expression and the promoter activity of HO-1 (heme oxygenase-1). Genes encoding cytoprotective proteins harbor antioxidant response elements (ARE), alternatively known as electrophile response elements.

In animal studies, intraperitoneal injection of carnosol (100–400 mg/kg) in female Sprague–Dawley rats led to a 1.6- to 1.9-fold increase in glutathione-S-transferase (GST) activity and a 3.1- to 4.8-fold increase in NAD(P)H-quinone reductase (QR) activity, two enzymes involved in detoxification of chemical substances.

Anti-Inflammatory Mechanisms

The anticancer and anti-inflammatory effects of carnosol are mediated by the inhibition of several signalling molecules including extracellular signal-regulated kinase (ERK), p38, c-Jun N-terminal kinase (JNK), Akt, mechanistic target of rapamycin (mTOR) and cyclooxygenase-2 (COX-2). Additionally, carnosol prevents the nuclear translocation of NF-κB and promotes apoptosis, as indicated by increased levels of cleaved caspase-3, -8, -9, increased levels of the pro-apoptotic marker BAX, and reduced levels of the anti-apoptotic marker Bcl-2.

Beyond its antioxidant activity, carnosol demonstrates anti-inflammatory effects in neural systems. It inhibits the phosphorylation and activation of inhibitor of kappa B alpha (IκBα) and p65, leading to reduced NF-κB-mediated neuroinflammation.

In macrophage assays, carnosol decreases nitric oxide (NO) production in mouse peritoneal exudate macrophages when used at concentrations ranging from 6 to 25 µM. Additionally, it inhibits 5-lipoxygenase (5-LO; IC₅₀ = 0.1 µM for the recombinant human enzyme) and the synthesis of leukotrienes in human polymorphonuclear leukocytes (PMNs; IC₅₀ = 7 µM). In lipopolysaccharide (LPS)-stimulated macrophage cell lines, carnosol reduced LPS-stimulated NO production with an IC₅₀ of 9.4 µM.

Anti-Cancer Mechanisms

Carnosol has been evaluated for anti-cancer properties in prostate, breast, skin, leukemia, and colon cancer with promising results. These studies have provided evidence that carnosol targets multiple deregulated pathways associated with inflammation and cancer, including NF-κB, apoptotic-related proteins, PI3K/Akt, and androgen and estrogen receptors.

In breast cancer cell lines, carnosol induces a ROS-dependent type I and type II programmed cell death (apoptosis and autophagy, respectively), which occurred independently of each other. Chemical inhibition of autophagy had no effect on the induction of apoptosis. Electron microscopy revealed that carnosol-treated cells exhibited enlarged endoplasmic reticulum, characteristic of ER stress. Markers of the three unfolded protein response pathways (PERK, IRE-1α, and ATF6) were upregulated in a ROS-dependent manner. In addition, carnosol induced a ROS-dependent activation of p38MAPK, increased the overall level of protein polyubiquitination, and targeted mTOR protein to proteasome degradation.

In gastric cancer models, carnosol is an RSK2 inhibitor that attenuates gastric cancer growth. Carnosol reduced anchorage-dependent and -independent gastric cancer growth by inhibiting the RSKs-CREB signaling pathway. The results of in vitro screening and cell-based assays indicated that carnosol represses RSK2 activity and its downstream signaling. Carnosol increased the G2/M phase and decreased S phase cell cycle, and also induced apoptosis through the activation of caspases 9 and 7 and inhibition of Bcl-xL expression.

Regarding anti-angiogenic properties, studies have examined the antiangiogenic properties of carnosol and carnosic acid, two major dietary compounds from rosemary, suggesting they may inhibit tumor vascularization. Due to its structural similarity to sex hormones, carnosol has been shown to inhibit the growth of prostate and breast cancers by binding to estrogen and androgen receptors, respectively.

Neuroprotective Mechanisms

For neuroprotection, carnosol and its related diterpenes in rosemary operate through the PINK1/parkin and SIRT1/p66shc pathways. A 2025 study published in Antioxidants reported that carnosol inhibited vincristine-induced hyperalgesia symptoms, suppressed the loss of intra-epidermal nerve fibers in vivo, and reduced the blood fluid level of phosphorylated neurofilament-H caused by an axonal degeneration event. These results indicate that carnosol has a neuroprotective effect via SARM1 inhibition in addition to its previously known antioxidant effect via NF-E2-related factor 2, and thus suppresses neurotoxin-induced peripheral neuropathy.

Antidiabetic Mechanisms

The anti-inflammatory mechanisms for carnosol's effects involve the NF-κB, MAPK, and Nrf2 pathways, all of which are implicated in the pathophysiology of insulin resistance and diabetes. In adipocyte models, carnosol and its parent compound carnosic acid have been shown to inhibit adipocyte differentiation in mouse 3T3-L1 cells through induction of phase-2 enzymes and activation of glutathione metabolism.

4. Scientific Evidence by Area of Use

Important Overarching Caveat

As of the time of writing, no published clinical trials have been conducted specifically on isolated carnosol as a dietary supplement in human subjects. To the knowledge of researchers in this field, no clinical trial has been conducted on carnosol as a compound. All human-relevant evidence derives from: (a) in vitro cell culture studies; (b) in vivo animal models; and (c) epidemiological associations with diets rich in rosemary and sage as whole herbs. The evidence base is therefore preliminary and not directly translatable to clinical human outcomes for the isolated compound.

4.1 Cancer Chemoprevention

Evidence level: Preclinical only (in vitro and animal models).

Multiple lines of evidence suggest that carnosol, a phenolic diterpene present in rosemary, holds the promise of preventing certain types of cancer. The most extensively studied cancer types are breast, prostate, skin (non-melanoma), leukemia, colon, and gastric cancers.

Treatment of breast cancer, prostate cancer, and skin cancer cells with carnosol significantly reduced cell viability, colony formation, and cell proliferation, and induced G2/M cell cycle arrest and apoptosis.

For skin cancer, in vitro work using the UVB/keratinocyte model showed that carnosol could reduce UVB-induced formation of cyclobutane pyrimidine dimers (CPDs) in keratinocytes, possibly through its ability to absorb UVB radiation. In addition, carnosol could inhibit the UVB-induced activation of NF-κB and reduce UVB-induced transformation of keratinocytes.

For gastric cancer, an in vivo mouse xenograft study reported that oral administration of carnosol suppressed patient-derived gastric tumor growth in an in vivo mouse model. These findings suggest carnosol is an RSK2 inhibitor that could be useful for treating gastric cancer.

For mammary cancer, an in vivo rodent study showed that carnosol (200 mg/kg) reduces mammary DNA adduct formation and tumorigenesis in a rat model of DMBA-induced mammary tumorigenesis.

For gingival/oral carcinoma, a 2024 in vitro study in Scientific Reports found that carnosol mediated colony formation and proliferation suppression in addition to cytotoxicity induction. Cell cycle arrest was highlighted by the disruption of the c-myc oncogene/p53 tumor suppressor balance. Carnosol also increased apoptosis, oxidative stress, and antioxidant activity. On a larger scale, the alteration of cell cycle and apoptotic profiles was demonstrated by QPCR array, most likely achieved by controlling the STAT5, ERK1/2, p38, and NF-κB signaling pathways. Carnosol reduced inflammation and invasion ability by modulating IL-6 and MMP9/TIMP-1 axes.

Limitation: More animal studies should be conducted, including studies on the pharmacokinetics of carnosol, to identify optimal dosage and routes of administration, as well as xenograft studies to better understand the tumor-reducing potential of carnosol before it can be used towards cancer treatment. There are no human clinical trials.

4.2 Anti-Inflammatory Effects

Evidence level: In vitro and animal models only.

Carnosol has been studied for its extensive antioxidant, anti-inflammatory, and anticancer effects. In cancer cells, carnosol has been demonstrated to inhibit cell proliferation and survival, reduce migration and invasion, and significantly enhance apoptosis. The anti-inflammatory effects are also documented in non-cancer contexts.

In a mouse model of vascular injury, the alleviating effect of carnosol (20 mg/kg) administered intraperitoneally before intratracheal instillation of diesel exhaust particles (DEP) was assessed. Carnosol administration prevented the increase in the plasma concentrations of C-reactive protein, fibrinogen, and tissue factor induced by DEP exposure.

Limitation: Anti-inflammatory evidence is entirely preclinical. In vitro concentrations demonstrating effect may not be achievable in human tissues through oral supplementation with current formulations.

4.3 Antioxidant Activity

Evidence level: In vitro and animal models; no standalone human trials for carnosol.

Carnosol (5–20 µM) treatment of microglia cells for 6 and 24 h was able to induce Nrf2 as well as heme oxygenase-1, an enzyme involved in counteracting oxidative stress, with minimal cytotoxicity. These studies show carnosol to exhibit antioxidant properties by directly scavenging free radicals as well as inducing cellular pathways that counteract oxidative stress. However, more studies are required to investigate whether carnosol acts as a pro-oxidant or antioxidant in cancer cells in vitro and in clinical studies, as the dual roles of ROS-modulating compounds in cancer versus normal cells are pharmacologically complex.

4.4 Neuroprotection

Evidence level: In vitro and animal models, with one recent animal study (2025).

Rosemary, the primary source of carnosol, has long been known to have neuroprotective effects due to its antioxidant and anti-inflammatory properties. Rosemary has been reported for its unusual druggable role in neuronal protection via multiple mechanisms.

In the context of dopaminergic neuroprotection, a published study in Neuroreport (2006) reported that carnosol, a component of rosemary, protects nigral dopaminergic neuronal cells.

A 2025 study found that carnosol inhibits SARM1 (Sterile Alpha and Toll/Interleukin-1 Receptor Motif-Containing 1) NAD+ cleavage activity — a mechanism linked to axonal degeneration — and demonstrated that carnosol inhibited vincristine-induced hyperalgesia symptoms, suppressed the loss of intra-epidermal nerve fibers in vivo, and reduced the blood level of phosphorylated neurofilament-H caused by axonal degeneration. These results indicate that carnosol has a neuroprotective effect via SARM1 inhibition in addition to its previously known antioxidant effect via Nrf2, and thus suppresses neurotoxin-induced peripheral neuropathy.

Limitation: All neuroprotective evidence is in vitro or in animal models. Human clinical evidence is absent for carnosol specifically.

4.5 Antidiabetic and Metabolic Effects

Evidence level: Animal models only.

A study published in Cardiovascular & Hematological Disorders–Drug Targets (2017) examined antidiabetic activity directly. Carnosol is an ortho-diphenolic diterpene in rosemary with great antioxidant potential. The study was designed to investigate the hypolipidemic, anti-oxidant, and anti-diabetic activities. In the experiment, rats were divided into groups of 8 animals each: control, untreated diabetic, and three carnosol (1, 5, 10 mg/kg/day)-treated diabetic groups. At the end of the experimental period, serum levels of glucose, IL-6, TNF-α, malondialdehyde (MDA), glutathione-S-transferase (GST), superoxide dismutase (SOD), catalase (CAT) activities, triglycerides (TG), total cholesterol (TC), LDL-C, and HDL-C were assessed. The investigation proposed that carnosol may improve diabetes and its complications by modulation of oxidative stress and inflammatory responses.

Limitation: The study used intraperitoneal (not oral) administration and a chemically induced diabetes model in rats, limiting direct translational relevance to human diabetes.

4.6 Cardiovascular and Vascular Protection

Evidence level: Animal models only.

The Mediterranean diet and herbs are known to be associated with decreased risks of cardiovascular and diabetic diseases. At the level of carnosol specifically, the evidence is animal-based. The mouse study of diesel exhaust particle-induced vascular injury described above (Section 4.2) provides mechanistic evidence in this domain, where carnosol prevented increases in inflammatory coagulation markers.

Reactive oxygen species and depletion of anti-oxidant enzymes have been suggested to promote biological responses including neurodegenerative and inflammatory conditions, cardiovascular disease, and carcinogenesis of various tissues, providing the theoretical basis for studying carnosol's cardiovascular relevance.

Limitation: Epidemiological associations between Mediterranean herb consumption and cardiovascular risk reduction apply to whole dietary patterns, not to isolated carnosol.

4.7 Antimicrobial Activity

Evidence level: In vitro only.

Extracts of rosemary and sage have been demonstrated to have antioxidant, antimicrobial, antidiabetic, and anticancer properties with minimal toxicity. Carnosol has been identified as a major component of these extracts contributing to antimicrobial effects. In Lepechinia hastata, carnosol was specifically isolated and characterized as a "diterpene antibiotic." In vitro studies have demonstrated activity against a range of bacterial strains, though whether such concentrations are achievable in human tissues through supplementation has not been tested.

5. Body Systems and Health Areas

The body systems and health areas associated with carnosol in the published literature, based exclusively on preclinical evidence, include:

• Oncology / Cancer biology: Demonstrated pro-apoptotic, antiproliferative, and anti-invasive effects across multiple cancer cell lines (breast, prostate, colon, skin, gastric, leukemia, oral).
• Immune and inflammatory system: NF-κB, COX-2, MAPK, and lipoxygenase pathway inhibition; reduced NO and leukotriene production.
• Antioxidant defense: Nrf2/ARE pathway activation, induction of HO-1, GST, NQO-1, and direct radical scavenging.
• Nervous system: Dopaminergic neuroprotection, SARM1 inhibition relevant to axonal degeneration, Nrf2-mediated anti-neuroinflammatory effects.
• Metabolic / Endocrine system: Glucose-lowering and lipid-normalizing effects in diabetic rodent models; inhibition of adipocyte differentiation.
• Cardiovascular system: Reduction of pro-thrombotic and pro-inflammatory vascular markers in mouse models.
• Skin: UVB-absorbing properties, inhibition of UVB-induced DNA damage and NF-κB activation in keratinocytes.
• Gastrointestinal / Digestive system: Tissue distribution studies show carnosol reaches the stomach, duodenum, jejunum, ileum, and liver after oral administration.

6. Dosage Forms and Dosages Reported in Studies

Because no clinical trials have been conducted on isolated carnosol in humans, there are no established human therapeutic doses. The following are doses reported in preclinical research and regulatory assessments:

• In vitro (cell culture) studies: Effective concentrations are typically in the range of 5–25 µM for antioxidant and anti-inflammatory endpoints; carnosol at 5–20 µM treatment of microglia cells induced Nrf2 and heme oxygenase-1 with minimal cytotoxicity.
• In vitro (LPS-stimulated macrophages): Carnosol reduced LPS-stimulated NO production with an IC₅₀ of 9.4 µM.
• 5-Lipoxygenase inhibition (cell-free): IC₅₀ = 0.1 µM for recombinant human 5-LO; IC₅₀ = 7 µM for leukotriene synthesis in human PMNs.
• Animal models — antioxidant enzyme induction: Intraperitoneal injection of carnosol at 100–400 mg/kg in female Sprague–Dawley rats induced significant increases in GST and QR activity.
• Animal models — anti-diabetic: Carnosol at 1, 5, and 10 mg/kg/day (injected intraperitoneally) in streptozotocin-induced diabetic rats over 4 weeks.
• Animal models — vascular protection: Carnosol at 20 mg/kg administered intraperitoneally 1 hour before intratracheal instillation of diesel exhaust particles in mice.
• Animal models — pharmacokinetics: Mice were administered carnosol at 100 mg/kg body weight by oral gavage; the maximum plasma concentration exceeded 1 µM after a single administration.
• Animal models — typical dose range: In the scientific literature, carnosol is most often evaluated in animal models through dietary administration or oral gavage. Current dose estimates are typically between 10 and 200 mg/kg body weight in mice and rats.
• Regulatory ADI (combined carnosic acid + carnosol): In 2016, the Joint FAO/WHO Expert Committee on Food Additives (JECFA) established a temporary acceptable daily intake (ADI) of 0–0.3 mg/kg body weight for rosemary extract, expressed as carnosic acid plus carnosol.
• NOAEL (90-day rodent study): The investigative 90-day study NOAEL providing 64 mg/kg bw/day carnosol and carnosic acid (the primary antioxidant components) was used to establish the temporary ADI for rosemary extracts.

Although many studies have provided evidence of the beneficial effects of carnosol against different diseases, only a limited number of studies have examined its bioavailability and pharmacokinetics. Oral administration of 100 mg of rosemary extract (RE) enriched with carnosic acid to lean female Zucker rats produced a plasma carnosol concentration of 18.2 µM. Furthermore, oral administration of RE resulted in carnosol being detected in tissues of the stomach, duodenum, jejunum, ileum, and liver, with only trace amounts in the brain. These studies indicate that oral administration of rosemary extract, which contains carnosol, can result in blood carnosol levels in the micromolar range and significant levels in different tissues in the body.

7. Safety Considerations and Drug Interactions

General Tolerability in Animal Studies

Carnosol appears to be well tolerated in that it has a selective toxicity towards cancer cells versus non-tumorigenic cells, and is well tolerated when administered to animals. Acute toxicity studies by single oral gavage in rats demonstrated no adverse effects observed at 2000 mg/kg body weight.

Regulatory Safety Assessment

Rosemary extracts containing carnosol as a defined component are used as permitted food additives in both the United States and the European Union. Extracts of rosemary (E 392) are authorized for use as food additives in the EU in several food categories with maximum levels. JECFA concluded that there are sufficient data to establish an ADI for rosemary extract, establishing a temporary ADI of 0–0.3 mg/kg body weight expressed as carnosic acid plus carnosol.

Enzyme analysis in a 90-day rat feeding study revealed reversible induction of cytochrome P450 enzymes (CYP2A1, CYP2A2, CYP2C11, CYP2E1, and CYP4A), demonstrating that the hepatic effects were adaptive and of no toxicological concern. Therefore, the highest dietary concentrations were established as the NOAELs.

Cytochrome P450 Inhibition and Drug Interaction Potential

A 2021 pharmacokinetic study published in Toxicology and Applied Pharmacology provided the first characterization of carnosol's interaction with the cytochrome P450 (CYP) drug-metabolizing enzyme system. The study investigated the potential for human cytochrome P450 enzyme inhibition of isoforms CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and modulation of known transporters. Evidence was found that carnosol may inhibit selected P450 enzymes and possibly disrupt selected transporters. This data is significant considering that rosemary extracts containing carnosol are being used as food preservatives in the United States and the European Union. The results are significant as they offer insights on the potential for food-drug interactions between carnosol from rosemary and active pharmaceutical ingredients.

Carnosol was observed to inhibit selected CYP450 enzymes and modulate metabolic enzymes and transporters in in vitro assays. These findings, while important as signals, were generated in vitro and in a single-dose mouse pharmacokinetic study. Their clinical significance at physiologically relevant concentrations attained through dietary supplementation has not been established in humans.

Contact Dermatitis Risk (for Whole Plant)

At the level of the whole plant preparation, rosemary has been reported as a cause of contact dermatitis. This is an established adverse effect for the whole herb and its essential oil preparations (not specifically attributed to carnosol).

Selective Cytotoxicity

Carnosol appears to be well tolerated in that it has selective toxicity towards cancer cells versus non-tumorigenic cells and is well tolerated when administered to animals. However, the selectivity of this toxicity, and whether it holds at doses achievable in humans through oral supplementation, remains to be confirmed in clinical settings.

Absence of Human Safety Data for Isolated Carnosol

There are currently no published Phase I, Phase II, or other clinical safety trials for isolated carnosol administered to humans as a defined pharmaceutical or supplement ingredient. To the knowledge of researchers active in this field, no clinical trial has been conducted on the compound. Safety assessments at the food additive level (JECFA, EFSA) pertain to the combination of carnosic acid plus carnosol as found in approved rosemary extract preparations, not to isolated carnosol administered therapeutically.

Summary of Evidence Strength

Carnosol is a well-characterized phytochemical with a rich body of in vitro and preclinical animal data supporting antioxidant, anti-inflammatory, anticancer, antidiabetic, neuroprotective, and antimicrobial properties. The molecular mechanisms underlying these effects — particularly NF-κB suppression, Nrf2 activation, PI3K/Akt modulation, SARM1 inhibition, and multi-caspase-mediated apoptosis induction — are well documented at the cellular level. However, no human clinical trials exist for isolated carnosol, and the compound's pharmacokinetics in humans have not been formally characterized. Bioavailability data from animal studies suggest that orally administered rosemary extract can deliver carnosol to systemic circulation and several tissues, but whether micromolar plasma concentrations achievable from food-relevant doses are sufficient to produce the in vitro effects observed at similar concentrations remains an open and critical research question. Further research on its precise pharmacological mechanisms is required before it can be reliably used to treat human diseases.

References

• Johnson JJ (2014). Carnosol: a phenolic diterpene with cancer chemopreventive potential. PubMed PMID 25337578.
• Johnson JJ (2011). Carnosol: a promising anti-cancer and anti-inflammatory agent. PubMed PMID 21382660.
• Ghasemzadeh Rahbardar M, et al. (2020). Anticancer Properties of Carnosol: A Summary of In Vitro and In Vivo Evidence. PMC7600884.
• ScienceDirect Topics: Carnosol — Overview (Medicine and Dentistry).
• PubChem (NIH): Carnosol, CID 442009.
• Murata H, et al. (2025). Carnosol, a Rosemary Ingredient Discovered in a Screen for Inhibitors of SARM1-NAD+ Cleavage Activity, Ameliorates Symptoms of Peripheral Neuropathy. PMC12291994.
• Alsamri H, et al. (2022). Carnosol Induces p38-Mediated ER Stress Response and Autophagy in Human Breast Cancer Cells. Front Oncol. PMC9194514.
• Cho HJ, et al. (2018). Carnosol suppresses patient-derived gastric tumor growth by targeting RSK2. PMC6188138.
• Tong L, Wu S (2018). The Mechanisms of Carnosol in Chemoprevention of Ultraviolet B-Light-Induced Non-Melanoma Skin Cancer Formation. Sci Rep. PMC5824785.
• Gandini S, et al. (2014). Carnosol: A Phenolic Diterpene With Cancer Chemopreventive Potential. PMC4204164.
• Anticancer Properties of Carnosol on Gingiva Carcinoma. Scientific Reports / PMC11133392 (2024).
• Mirza FJ, et al. (2023). Neuroprotective Effects of Carnosic Acid: Insight into Its Mechanisms of Action. PMC10005014.
• Samarghandian S, Borji A (2017). Evaluation of Antidiabetic Activity of Carnosol in Streptozotocin-Induced Diabetic Rats. PubMed PMID 28034282.
• Palliative effects of carnosol on lung-deposited pollutant particles-induced thrombogenicity and vascular injury in mice. PMC11110483 (2024).
• Vemu B, et al. (2021). Pharmacokinetic characterization of carnosol from rosemary in male C57BL/6 mice and inhibition profile in human cytochrome P450 enzymes. Toxicol Appl Pharmacol.
• Vemu B, et al. (2021). Pharmacokinetic characterization of carnosol from rosemary (Salvia Rosmarinus) in male C57BL/6 mice and inhibition profile in human cytochrome P450 enzymes. PubMed PMID 34592323.
• EFSA Panel on Food Additives (2020). Refined exposure assessment of extracts of rosemary (E 392) as food additive. PMC7009710.
• Critical review on biological effect and mechanisms of diterpenoids in Rosmarinus officinalis. Functional Medicine and Health (2025).
• ScienceDirect Topics: Carnosol — Overview (Neuroscience).
• American Herbal Products Association: Herbs in History — Rosemary.
• Andrade JM, et al. (2016). A novel insight on an ancient aromatic plant: Rosmarinus officinalis L. Trends in Food Science & Technology.
• Drugs.com Natural Products Database: Rosemary (Rosmarinus officinalis).